Deucravacitinib Improves Patient-Reported Outcomes in Active

The selective, allosteric tyrosine kinase 2 inhibitor demonstrated significant and clinically meaningful improvements in PROs versus placebo in a phase 2 trial of patients with PsA.

Related Keywords

, American College Of Rheumatology , Health Assessment Questionnaire , Short Form Health , Stanford University School Of Medicine , American College , Health Assessment Questionnaire Disability Index , Physical Component Summary , Vibeke Strand , Stanford University School , Classification Criteria , Psoriatic Arthritis , Psoriatic Impact , Functional Assessment , Chronic Illness Therapy Fatigue , Patient Global Assessment , Disease Activity ,